SHARE     PRINT

Expertise Applied to Advancing Treatment for Respiratory Disease

For the millions of people who suffer from respiratory diseases, each breath is a major accomplishment. Those people include patients with chronic lung problems, such as asthma, bronchitis, and emphysema, but they also include heart attack and accident victims, premature infants, and people with cystic fibrosis, lung cancer, or AIDS. Millions of people in the U.S. have lung disease. If all types of lung diseases are combined, it is the number three killer in the United States.

SynteractHCR has notable experience in conducting Phase I-IV respiratory clinical trials, and have conducted 75 drug and device studies in more than 8,300 patients. We have strong relationships with clinical investigators and key opinion leaders to help you meet your respiratory trial goals. With our therapeutic and clinical expertise, we focus together on your needs, and strategically customize services for each project, to deliver as promised at a competitive price. That allows our pharmaceutical and biotech clients to make decisions quickly and move their development programs forward at a rapid pace.

SynteractHCR Respiratory Expertise

  • Allergic Rhinitis
  • Asthma
  • COPD
  • Chronic Bronchitis
  • Cystic Fibrosis
  • Emphysema
  • Idiopathic Pulmonary Fibrosis
  • Pneumothoraces associated with needle lung biopsies
  • Respiratory Distress Syndrome

Related Links

Well-rounded experience.

SynteractHCR has conducted
trials across all major
therapeutic areas and
we have contributed 
to more than 230
product approvals
since our
founding.
Learn More

Contact SynteractHCR

  • USA: +1 760 268 8200
  • Europe: +49 89 12 66 80 0
  • Contact Form...

Contact SynteractHCR

Tell us how to stay in touch with you:


Required Fields(*)
Cancel